Recombinant bovine immunodeficiency virus gag virus-like particles containing influenza immunogens
AssigneeMedigen, Inc.
InventorsPeter Pushko, Irina Tretyakova
Life of this patent
Estimating the term…
Abstract
Described herein, are Bovine immunodeficiency virus gag protein (“Bgag”) recombinant virus like particles (“VLPs”) including one or more different types of target pathogen proteins. Also described, are compositions including the Bgag VLPs and the methods of making and using the novel Bgag VLP.
Claims15
A bovine immunodeficiency virus Gag (Bgag) virus-like particle (VLP) comprising one or more different Influenza virus hemagglutinin (HA) and/or neuraminidase (NA) transmembrane proteins, wherein said proteins are integrated into the lipid bilayer of the VLP.
A pharmaceutical composition comprising a bovine immunodeficiency virus Gag (Bgag) virus-like particle (VLP) comprising one or more different Influenza virus hemagglutinin (HA) and/or neuraminidase (NA) transmembrane proteins, wherein said proteins are integrated into the lipid bilayer of the VLP and a suitable pharmaceutical excipient.
A method of making a bovine immunodeficiency virus Gag (Bgag) virus-like particle (VLP) comprising one or more different Influenza virus hemagglutinin (HA) and/or neuraminidase (NA) transmembrane proteins, wherein said proteins are integrated into the lipid bilayer of the VLP, the method comprising the following:
- a) introducing a transfer vector encoding Bgag and one or more Influenza HA and NA proteins into a cell under conditions that allow expression and formation of the Bgag VLP comprising one or more Influenza antigens;
- and,
- b) recovering and purifying the Bgag VLPs from the cell or a culture medium carrying the cell.
A method of making a pharmaceutical composition comprising a bovine immunodeficiency virus Gag (Bgag) virus-like particle (VLP) comprising one or more different Influenza virus hemagglutinin (HA) and/or neuraminidase (NA) transmembrane proteins, wherein said proteins are integrated into the lipid bilayer of the VLP and a suitable pharmaceutical excipient, the method comprising mixing the Bgag VLP and one or more suitable pharmaceutical excipient.
Dependencies are inferred from the claim text.